# Sorafenib and Bevacizumab in Combination With Paclitaxel in Patients With Solid Tumors

> **NCT00572078** · PHASE1 · COMPLETED · sponsor: **Safi Shahda** · enrollment: 27 (actual)

## Conditions studied

- SOLID TUMORS

## Interventions

- **DRUG:** Sorafenib

## Key facts

- **NCT ID:** NCT00572078
- **Lead sponsor:** Safi Shahda
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-01-23
- **Primary completion:** 2011-01-04
- **Final completion:** 2014-09-14
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2017-09-25

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00572078

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00572078, "Sorafenib and Bevacizumab in Combination With Paclitaxel in Patients With Solid Tumors". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00572078. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*